An artificial intelligence (AI) model that analyzes the results of echocardiograms may help predict the likelihood of transthyretin amyloid cardiomyopathy (ATTR-CM) in people…
News
Researchers have identified a common structure among toxic transthyretin (TTR) clumps, called amyloid fibrils, in heart tissue from people carrying mutations linked to hereditary…
In people with transthyretin amyloid cardiomyopathy (ATTR-CM), the buildup of faulty transthyretin (TTR) protein in the heart may contribute to blood clots that block…
Increased levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with more severe neurological symptoms in people with hereditary transthyretin…
People with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in more recent clinical trials show less advanced disease and improved survival compared with those in earlier studies,…
New analyses back the use of the approved therapy Amvuttra (vutrisiran) as an initial treatment for people with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)…
The injection therapy Wainua (eplontersen) “offers a vital ray of hope” for people living with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), an international…
New analyses suggest Attruby (acoramidis) may reduce the risk of outpatient worsening heart failure, with differences seen within 30 days and sustained through 30…
People with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) often experience eye-related complications such as eye dryness and floaters in the field of vision, according…
The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy…
Recent Posts
- Weighing the pros and cons of participating in a clinical trial
- Wrist biopsy may aid in early detection of heart disease
- Study links hATTR-PN mutations to symptoms beyond nerve damage
- Navigating the risk of falls with hATTR amyloidosis
- Trial evaluates drug’s potential to reverse ATTR-CM heart damage